22 March 2019 | News
Hyphens intends to develop innovative and differentiated dermatological products to address unmet market needs.
Hyphens is currently licensing sugar-based surfactant micro-emulsions technology from A*STAR’s Institute of Chemical and Engineering Sciences (ICES).
By leveraging A*STAR’s research and development capabilities, it is envisioned that this MoU will enable Hyphens to develop innovative and differentiated dermatological products to address unmet market needs.
Hyphens is a Singapore-headquartered ASEAN specialty pharma company. Operating in six countries across the region, Hyphens has a strong medical, regulatory and commercial capability. Dermatology is a key therapeutic focus field where Hyphens markets products under the brands “Ceradan” and “TDF”.